Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function.

Barnes N, Wei LX, Reiss TF, Leff JA, Shingo S, Yu C, Edelman JM.

Respir Med. 2001 May;95(5):379-86. Review.

2.

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL.

Pediatrics. 2001 Sep;108(3):E48.

PMID:
11533366
3.

Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%.

Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B.

Curr Med Res Opin. 2004 Oct;20(10):1651-9.

PMID:
15462699
4.
5.

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group.

Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, Seidenberg BC, Reiss TF.

Ann Intern Med. 1999 Mar 16;130(6):487-95.

PMID:
10075616
6.

A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group.

Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss TF.

J Allergy Clin Immunol. 1998 Jul;102(1):50-6.

PMID:
9679847
7.

Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability.

Zhang J, Yu C, Noonan G, Reiss TF.

Clin Ther. 2002 Apr;24(4):574-82.

PMID:
12017402
8.

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older.

Williams B, Noonan G, Reiss TF, Knorr B, Guerra J, White R, Matz J.

Clin Exp Allergy. 2001 Jun;31(6):845-54.

PMID:
11422148
9.

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.

Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF.

N Engl J Med. 1998 Jul 16;339(3):147-52.

10.

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, Kundu S, Zhang J.

J Allergy Clin Immunol. 1996 Sep;98(3):528-34.

PMID:
8828530
11.

Effectiveness of montelukast in the treatment of cough variant asthma.

Spector SL, Tan RA.

Ann Allergy Asthma Immunol. 2004 Sep;93(3):232-6.

PMID:
15478381
12.

The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma.

Yüksel B, Aydemir C, Ustündag G, Eldeş N, Kutsal E, Can M, Demirtaş S, Tomaç N.

Turk J Pediatr. 2009 Sep-Oct;51(5):460-5.

PMID:
20112601
13.

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.

Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, Edelman JM.

Ann Allergy Asthma Immunol. 2004 Jun;92(6):641-8.

PMID:
15237766
14.

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial.

Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S, Edwards L, Rickard K; Fluticasone Proprionate Clinical Research Study Group.

J Allergy Clin Immunol. 2001 Mar;107(3):461-8.

PMID:
11240946
15.

Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.

Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.

Clin Ther. 2008 Aug;30(8):1492-504. doi: 10.1016/j.clinthera.2008.07.018.

PMID:
18803991
16.

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge.

Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM; Challenge-Rescue Study Group.

Respir Med. 2004 Nov;98(11):1051-62.

PMID:
15526805
17.

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients.

Dockhorn RJ, Baumgartner RA, Leff JA, Noonan M, Vandormael K, Stricker W, Weinland DE, Reiss TF.

Thorax. 2000 Apr;55(4):260-5.

18.

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma.

Vaquerizo MJ, Casan P, Castillo J, Perpiña M, Sanchis J, Sobradillo V, Valencia A, Verea H, Viejo JL, Villasante C, Gonzalez-Esteban J, Picado C; CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group.

Thorax. 2003 Mar;58(3):204-10. Erratum in: Thorax. 2003 Apr;58(4):370.

19.

Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial.

Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ, Hustad CM, Edelman JM.

Am J Med. 2005 Jun;118(6):649-57.

PMID:
15922697
20.

Effect of montelukast on peripheral airflow obstruction in children with asthma.

Spahn JD, Covar RA, Jain N, Gleason M, Shimamoto R, Szefler SJ, Gelfand EW.

Ann Allergy Asthma Immunol. 2006 Apr;96(4):541-9.

PMID:
16680924

Supplemental Content

Support Center